Ichiro Kinoshita

Summary

Affiliation: Hokkaido University
Country: Japan

Publications

  1. pmc Expression of Bim, Noxa, and Puma in non-small cell lung cancer
    Jun Sakakibara-Konishi
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo, 060 8638, Japan
    BMC Cancer 12:286. 2012
  2. pmc Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
    Hiroshi Yokouchi
    First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
    BMC Cancer 7:51. 2007
  3. ncbi request reprint Expression of LGR5, an intestinal stem cell marker, during each stage of colorectal tumorigenesis
    Kayoko Takeda
    Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo 060 8638, Japan
    Anticancer Res 31:263-70. 2011
  4. pmc Clinicopathological significance of expression of p-c-Jun, TCF4 and beta-Catenin in colorectal tumors
    Kayoko Takeda
    Department of Medical Oncology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita ku, Sapporo 060 8638, Japan
    BMC Cancer 8:328. 2008
  5. doi request reprint Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer
    Junko Kikuchi
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo 060 8638, Japan
    Lung Cancer 72:229-37. 2011
  6. doi request reprint Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer
    Jun Sakakibara-Konishi
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo 060 8638, Japan
    Lung Cancer 74:248-52. 2011
  7. ncbi request reprint Expression of N-acetylglucosaminyltransferase V in the development of human esophageal cancers: immunohistochemical data from carcinomas and nearby noncancerous lesions
    Yoko Ishibashi
    Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Oncology 69:301-10. 2005
  8. ncbi request reprint Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
    Jun Konishi
    First Department of Medicine, Hokkaido University School of Medicine, Kita ku, Sapporo 060 8638, Japan
    Anticancer Res 25:435-41. 2005
  9. ncbi request reprint Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L
    Hajime Asahina
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo 060 8638, Japan
    Lung Cancer 54:419-22. 2006
  10. ncbi request reprint Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer
    Junko Kikuchi
    First Department of Medicine, Hokkaido University School of Medicine, Sapporo 060 8638, Japan
    Jpn J Clin Oncol 34:505-9. 2004

Collaborators

Detail Information

Publications21

  1. pmc Expression of Bim, Noxa, and Puma in non-small cell lung cancer
    Jun Sakakibara-Konishi
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo, 060 8638, Japan
    BMC Cancer 12:286. 2012
    ..In this study, we evaluated the expression of Bim, Noxa, and Puma in non-small cell lung cancer (NSCLC)...
  2. pmc Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
    Hiroshi Yokouchi
    First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
    BMC Cancer 7:51. 2007
    ....
  3. ncbi request reprint Expression of LGR5, an intestinal stem cell marker, during each stage of colorectal tumorigenesis
    Kayoko Takeda
    Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo 060 8638, Japan
    Anticancer Res 31:263-70. 2011
    ..The Wnt target LGR5 has been recently identified as a murine intestinal stem cell marker. Its role during each stage of human colorectal tumorigenesis remains to be determined...
  4. pmc Clinicopathological significance of expression of p-c-Jun, TCF4 and beta-Catenin in colorectal tumors
    Kayoko Takeda
    Department of Medical Oncology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita ku, Sapporo 060 8638, Japan
    BMC Cancer 8:328. 2008
    ..To determine the significance of these three proteins in human colorectal tumors, we analyzed their nuclear expression by immunohistochemistry...
  5. doi request reprint Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer
    Junko Kikuchi
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo 060 8638, Japan
    Lung Cancer 72:229-37. 2011
    ....
  6. doi request reprint Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer
    Jun Sakakibara-Konishi
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo 060 8638, Japan
    Lung Cancer 74:248-52. 2011
    ..This study was conducted to determine the maximum tolerated dose (MTD) and recommended dose (RD) of paclitaxel in combination with carboplatin and concurrent real-time tumor-tracking thoracic radiation therapy (thoracic RTRT)...
  7. ncbi request reprint Expression of N-acetylglucosaminyltransferase V in the development of human esophageal cancers: immunohistochemical data from carcinomas and nearby noncancerous lesions
    Yoko Ishibashi
    Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Oncology 69:301-10. 2005
    ..However, neither GnT-V expression nor its clinical significance has been previously examined in human normal, premalignant and malignant esophageal tissues...
  8. ncbi request reprint Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
    Jun Konishi
    First Department of Medicine, Hokkaido University School of Medicine, Kita ku, Sapporo 060 8638, Japan
    Anticancer Res 25:435-41. 2005
    ..We analyzed the efficacy, toxicity and overall survival time of gefitinib treatment in patients with NSCLC...
  9. ncbi request reprint Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L
    Hajime Asahina
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo 060 8638, Japan
    Lung Cancer 54:419-22. 2006
    ..Disease progressed during 6 weeks of treatment. This case suggests that in vitro sensitivity to gefitinib correlates with distinct clinical responsiveness to gefitinib in various types of EGFR mutations...
  10. ncbi request reprint Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer
    Junko Kikuchi
    First Department of Medicine, Hokkaido University School of Medicine, Sapporo 060 8638, Japan
    Jpn J Clin Oncol 34:505-9. 2004
    ....
  11. ncbi request reprint E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells
    Nobuyuki Hakuma
    First Department of Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Cancer Res 65:10776-82. 2005
    ..These results suggest that E1AF activates the Rho/ROCK pathway in an HGF-enhanced manner and its activation is important in E1AF-induced motility and invasion as well as tumorigenesis and metastasis in NSCLC cells...
  12. ncbi request reprint [Non-small-cell lung cancer]
    Hirotoshi Akita
    Dept of Medical Oncology, Hokkaido University Graduate School of Medicine, Kita ku, Sapporo, Japan
    Gan To Kagaku Ryoho 35:720-4. 2008
    ..Multi-target tyrosine kinase inhibitors in combination with standard chemotherapy, and anti-EGFR antibodies and EGFR tyrosine kinase inhibitors in combination with thoracic radiotherapy, are under clinical trials...
  13. pmc A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
    Satoshi Takeuchi
    Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Case Rep Oncol 4:260-6. 2011
    ..Dramatic tumor shrinkage was obtained, and a partial response was achieved. This case suggests that high-grade neuroendocrine carcinoma can be treated with bevacizumab in combination with cytotoxic chemotherapy...
  14. doi request reprint 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts
    Satoshi Takeuchi
    Department of Medical Oncology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060 8638, Japan
    Oncol Rep 26:725-30. 2011
    ..01). These results suggest that 18F-FLT-PET/CT can be a useful predictor to determine the response to molecular targeted drugs such as cetuximab at an earlier time point than the change of tumor size...
  15. ncbi request reprint Establishment and characterization of amylase-producing lung adenocarcinoma cell line, IMEC-2
    Hiroshi Yokouchi
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo, Japan
    Anticancer Res 26:2821-7. 2006
    ..Few studies have successfully established an amylase-producing lung cancer cell line or have examined its cytological, biochemical and biological features...
  16. ncbi request reprint Epithelioid sarcoma presenting as pulmonary cysts with cancer antigen 125 expression
    Eiki Kikuchi
    First Department of Medicine, Hokkaido University Hospital and School of Medicine, Sapporo, Japan
    Respirology 11:826-9. 2006
    ..However, presence of cancer antigen 125 hindered obtaining a correct diagnosis of ES...
  17. pmc Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells
    Masahisa Jinushi
    Division of Signaling in Cancer and Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
    Proc Natl Acad Sci U S A 108:12425-30. 2011
    ..Thus, the pharmacological targeting of key factors derived from tumor-associated inflammation provides a unique strategy to eradicate therapy-resistant tumors by manipulating CSC activities...
  18. ncbi request reprint Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers
    Toshiyuki Harada
    First Department of Medicine, Hokkaido University School of Medicine, Kita ku, Sapporo 060 8638, Japan
    Cancer Sci 94:394-9. 2003
    ..These findings indicate that immunostaining for P53 and LRP using TBB specimens may be useful for dividing patients with NSCLC into chemoresponsive and chemoresistant groups...
  19. ncbi request reprint [Superior vena cava syndrome]
    Jun Taguchi
    Dept of Medical Oncology, Hokkaido University Graduate School of Medicine, Japan
    Gan To Kagaku Ryoho 38:518-23. 2011
    ..The presence of the SVC syndrome does not reduce the likelihood ofa cure for the underlying malignant condition, and should not compromise the choice of appropriate therapy...
  20. ncbi request reprint Retinoic acid inhibits interleukin-4-induced eotaxin production in a human bronchial epithelial cell line
    Kei Takamura
    1st Dept of Medicine, Hokkaido Univ School of Medicine, North 15, West 7, Kita ku, Sapporo 060 8638, Japan
    Am J Physiol Lung Cell Mol Physiol 286:L777-85. 2004
    ..These findings raise the possibility that RA may reduce eosinophilic airway inflammation, one of the prominent pathological features of allergic diseases such as bronchial asthma...
  21. doi request reprint ATM-mediated DNA damage signals mediate immune escape through integrin-αvβ3-dependent mechanisms
    Masahisa Jinushi
    Research Center for Infection Associated Cancer, Institute for Genetic Medicine, Hokkaido University, Tokyo, Japan
    Cancer Res 72:56-65. 2012
    ..Furthermore, these findings suggest that integrin-αvβ3 targeting may benefit patients' refractory to current anticancer regimens by defeating DNA damage signaling-induced immune escape...